🇺🇸 FDA
Pipeline program

Isis 420915/GSK 299872

2015-P001574

Phase 2 small_molecule terminated

Quick answer

Isis 420915/GSK 299872 for Amyloidosis is a Phase 2 program (small_molecule) at IONIS PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
IONIS PHARMACEUTICALS INC
Indication
Amyloidosis
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials